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fiTo the Editor: It was recently reported that, compared with
placebo, 6 months of treatment with a modest dose of simva-
statin or pravastatin had an adverse effect on a summated
measure of energy and fatigue in 1,016 generally healthy men
and women (1). With a goal of verifying this observation, we
conducted a retrospective analysis of the effect of a statin on
fatigue in the 5,010 patients (1,180 women) with chronic
systolic heart failure randomized to receive placebo or rosuvas-
tatin 10 mg daily in the CORONA (Controlled Rosuvastatin
Multinational Trial in Heart Failure) study. Fatigue was mea-
sured at baseline, 6 weeks, and 3 months thereafter in this older
population.
The inclusion and exclusion criteria for CORONA have been
described in detail elsewhere (2,3). Briefly, eligible patients
were aged 60 years with symptomatic (New York Heart
Association class II through IV), ischemic, systolic (left ven-
tricular ejection fraction 40%) heart failure. The investigator
was asked to rate patient fatigue “during the past few days” by
using a 5-point scale (0  none; 1  on heavy exertion; 2  on
moderate exertion; 3  on slight exertion; 4  at rest). For the
purposes of analysis, only change in fatigue from baseline to the
7.5-month follow-up visit was analyzed. This method was used
to be most comparable to the study of Golomb et al. (1) and
because after that time-point, significant numbers of patients
experienced worsening heart failure or death. The difference
between treatments for change in fatigue was compared by
using a 2-sided Wilcoxon rank sum test, and proportions were
compared by using chi-square tests. Statistical significance was
set at a level of 0.05.
At baseline, the number of patients with grade 0, 1, 2, 3, and
4 fatigue was as follows: 233 (4.7%), 365 (7.3%), 1,940 (38.7%),
2,337 (46.7%), and 135 (2.7%), respectively. At 7.5 months,
4,653 (93%) patients had a measurement of fatigue compared
with 5,010 patients at baseline. Figure 1 shows the proportions
of patients reporting improvement, worsening, or no change in
fatigue between baseline and 7.5 months of follow-up. Com-
pared with placebo, 67 (2.8%) more statin-treated patients
reported worsening of fatigue and 25 (1.2%) fewer reported
improvement. Most showed no change (1,615 [69.1%] patients
receiving rosuvastatin and 1,638 [70.7%] patients receiving
placebo [overall p  0.01]). Sex did not influence the effect of
rosuvastatin (interaction tested in an ordinal logistic regression
model p  0.74). The number of patients reporting worsening
of 2 or more categories was 50 (2.1%) in the rosuvastatin group
and 52 (2.2%) in the placebo group (p  0.81). The number of
patients progressing to grade 3 fatigue over 7.5 months was 172
(7.4%) in the rosuvastatin group and 133 (5.7%) in the placebo
group, a difference of 39 (1.7%) patients (p  0.03). At 7.5
months, 946 (41%) rosuvastatin-treated patients and 919 (40%) fpatients receiving placebo had grade 3 fatigue (p  0.56). The
number of patients progressing to grade 4 fatigue over 7.5
months was 44 (1.9%) in the rosuvastatin group and 39 (1.7%)
in the placebo group (p  0.61); at 7.5 months, 70 (3.0%)
rosuvastatin-treated patients and 66 (2.9%) patients receiving
placebo had grade 4 fatigue (p  0.76).
In this post hoc analysis of a large, randomized, double-blind,
lacebo-controlled trial, we found some evidence that rosuvastatin
eads to worsening fatigue although most patients assigned to
tatin treatment showed no change in fatigue (as was the case in
he placebo group). There was no detectable excess of statin-
reated patients reporting large changes (worsening of 2 or more
ategories) in fatigue, and only a small excess (43 more) showed
rogression to the most severe forms (grades 3 and 4) of fatigue.
onsequently, the clinical significance of our findings is uncertain,
specially because we studied elderly patients with systolic heart
ailure who might have been particularly vulnerable to the adverse
ffects of a statin. There were some other differences between our
rial and that reported by Golomb et al. (1). We used a different
tatin, employed a simpler fatigue score (as opposed to a composite
f “energy” and “fatigue with exertion”), and did not find an
nteraction with sex.
Although we believe our findings to be robust (we studied a
arge number of patients, had nearly complete observations, and
id not have to impute missing data), the explanation of the
ndings is unclear; that is, it is uncertain why statins should cause
Figure 1 Change in Fatigue BetweenBaseline and 7.5 Months of Follow-up
Compared with placebo, a small excess (n  67 [2.8%]) of statin-treated
patients reported worsening of fatigue and 25 (–1.2%) fewer reported improve-
ment; most showed no change (1,615 [69.1%] rosuvastatin-treated patients
and 1,638 [70.7%] patients receiving placebo; overall p  0.01).atigue. The most likely explanation is an effect on skeletal muscle;
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March 12, 2013:1121–3however, there is no convincing evidence that low-dose statins
impair muscle function (4) or cause muscle-related adverse ef-
fectsmore frequently than placebo (as already reported in CO-
RONA), except, perhaps, for very rare cases of rhabdomyolysis
(5,6). Muscle-related adverse events are, however, clearly increased
with high-dose simvastatin treatment (7). An alternative explana-
tion is that statins might increase the perception of fatigue through
a central nervous system effect, but this possibility is less likely with
a hydrophilic agent such as rosuvastatin (8).
Although rosuvastatin led to worsening of fatigue in a small
roportion of older patients with systolic heart failure, the clinical
ignificance of this finding is uncertain.
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117–25.Letters to the Editor
Why Are We Still Using
Coronary Bare-Metal Stents?
In their paper, Singla et al. (1) describe accurately the dilemma
faced by cardiologists when confronted with a frequent occurrence
in which a potential conflict may arise between the need for
long-term dual antiplatelet therapy (DAPT) in recipients of
drug-eluting stents (DES) and common real-life situations such as
the need for noncardiac surgery.
Despite a wealth of data demonstrating the superiority of DES
versus bare metal stents (BMS) in all types of lesions/patients (2), a
significant proportion of patients still receive a BMS. One of the most
frequent reasons is that implanting a BMS allows a 1-month duration
of DAPT compared with a DES (6 to 12 months in the European
Society of Cardiology guidelines, 12 months in the American Heart
Association/American College of Cardiology guidelines) (3,4).
To elucidate why BMSs are still used today, we prospectively
collected data from 31 centers in Europe and Asia to identify the
main reason for implantation of BMS rather than DES in 744
consecutive percutaneous coronary interventions performed from
April to May 2012. Eight indications for using BMS were
identified: large vessel diameter, 241 (32.4%); ST-segment eleva-
tion myocardial infarction, 132 (17.7%); reimbursement/
regulatory/other reasons, 70 (9,4%); advanced age, 92 (12.4%);
concomitant oral anticoagulant treatment, 84 (11.3%); increased
bleeding risk, cancer, or anemia, 71 (9.5%); planned noncardiac
surgery within the next year, 41 (5.5%); and anticipated poor
DAPT compliance, 13 (1.7%).
This demonstrated that the use of a BMS was directly driven by
a concern about either bleeding or DAPT compliance in 301
(40.5%) cases. Although, as underlined by the authors, the risk of
stent thrombosis is at its highest when DAPT discontinuation
occurs during the first month after PCI, most interventions can be
postponed for 1 month, and the selection between BMS and DES
is then made in consideration of mid-term DAPT requirements (1
month only vs. 1 year).
This implies that a number of patients currently treated with a
BMS can be considered to have been deprived of a more efficacious
DES because of a concern about prolonged DAPT. Data have now
become available to support a 3- to 6-month course of DAPT after
DES implantation (5,6), but there is a real need for a device
combining the favorable effects of DES on restenosis and a DAPT
course of only 1 month when necessary.
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